Molecular biology of malignant degeneration of astrocytoma

Pediatric Neurosurgery

Volumn 24, Issue 1, 1996, Pages 41-49

  Furnari, Frank B ^a   Huang, H J Su ^a   Cavenee, Webster K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Genetics; Glioma; Malignant progression

Indexed keywords

GROWTH PROMOTOR;

ASTROCYTOMA; CANCER GRADING; CANCER GROWTH; CENTRAL NERVOUS SYSTEM TUMOR; CHROMOSOME 22Q; CONFERENCE PAPER; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GENETICS; GLIOMA; HUMAN; HUMAN TISSUE; MALIGNANT TRANSFORMATION; MOLECULAR BIOLOGY; PRIORITY JOURNAL; STEM CELL;

EID: 0030014240     PISSN: 10162291     EISSN: 14230305     Source Type: Journal    
DOI: 10.1159/000121013     Document Type: Article

References (109)

1. Nowell PC: The clonal evolution of tumor cell populations., Science 1976:194:23-28.
2. Levin VA., Gutin PH, Leibcl S: Neoplasms of the central nervous system; in De Vita VT Jr., Heilman S, Rosenberg SA (eds): Cancer Principles and Practice of Oncology., Philadelphia., Lippincott, 1993, pp 1679-1737.
3. Klcihues P., Burger PC, Scheithauer BW: Histological Typing of Tumors of the Central Nervous System., Berlin., Springer, 1993.
4. Chung R, Whaley J, Kiev N, Anderson K, Louis D., Menon A, Hettlich C, Freiman R, Hedley-Whyte ET., Martuza R: TP53 gene mutations and 17p deletions in human astrocytomas., Genes Chromosom Cancer 1991:3:323-331.
5. Fults D, Tippets RH, Thomas GA, Nakamura Y, White R: Loss of heterozygosity for loci on chromosome 17p in human malignant astrocytoma., Cancer Res 1989:49:6572-6577.
6. Fults D., Brocknteyer D., Tullous MW, Pedone CA, Cawthon RM: p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression., Cancer Res 1992:52:674-679.
7. James CD, Carlbom E, Nordenskjold M., Collins VP., Cavenee WK: Mitotic recombination of chromosome 17 in astrocytomas., Proc Natl Acad Sci USA 1989;86:2858-2862.
8. Nigro JM., Baker SJ., Preisinger AC, Jessup JM., Hosteller R., Cleary K., Bigner SH., Davidson N, Bavlin S, Dcvilcc P: Mutations in the p53 gene occur in diverse human tumour types., Nature 1989;342:705-708.
9. Frankel RH, Bayona W, Koslow M, Newcomb EW: p53 mutations in human malignant gliomas: Comparison of loss of heterozygosity with mutation frequency., Cancer Res 1992,52: 1427-1433.
10. Saxena A, Clark WC, Robertson JT, Ikejiri B, Oldfield EH., Ali IU: Evidence for the involvement of a potential second tumor suppressor gene on chromosome 17 distinct from p53 in malignant astrocytomas., Cancer Res 1992;52: 6716-6721.
11. Sidransky D., Mikkelsen T, Schwcchheimcr K., Rosenblum ML., Cavenee W, Vogelstein B: Clonal expansion of p53 mutant cells is associated with brain tumour progression., Nature 1992;355:846-847.
12. Von Deimling A, Eibl RH., Ohgaki H., Louis DN, von Ammon K, Petersen I., Kleihues P, Chung RY, Wiestler OD, Seizingcr BR: p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma., Cancer Res 1992:52:2987-2990.
13. Louis DN, von Deimling A, Chung RY, Rubio MP., Whaley JM, Eibl RH., Ohgaki H., Wiestler OD, Thor AD, Seizingcr BR: Comparative study of p53 gene and protein alterations in human astrocytomas., J Neuropathol Exp Neurol 1993:52:31-38.
14. Rasheed BK., McLendon RE, Herndon JE., Friedman HS, Friedman AH, Bigner DD., Bigner SH: Alterations of the TP53 gene in human gliomas., Cancer Res 1994:54:1324-1330.
15. Louis DN: The p53 protein in human brain tumors., J Neuropathol Exp Neurol 1994;53: 11-21.
16. Mercer WE., Shields MT, Amin M., Sauve GJ, Appella E, Romano JW, Ullrich SJ: Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53., Proc Natl Acad Sci USA 1990:87: 6166-6170.
17. Van Meir EG, Roemcr K., Discrens A-C, Kiku-chi T, Rempel SA., Haas M., Huang H-JS., Friedmann T, De Tribolet N, Cavenee WK: Single cell monitoring of growth arrest and morphological changes induced by transfer of wild-type p53 alleles to glioblastoma cells., Proc Natl Acad Sci USA 1995;92:1008-1012.
18. Biegel JA., Burk CD., Barr FG., Emanuel BS: Evidence for a 17p tumor-related locus distinct from p53 in pediatric primitive neuroectodermal tumors., Cancer Res 1992:52:3391-3395.
19. Rubio MP, von Deimling A., Yandell DW., Wiestler OD, Gusella JF, Louis DN: Accumulation of wild-type p53 protein in human astrocytomas., Cancer Res 1993:53:3465-3467.
20. Reifenberger G, Reifenberger J., lchimura K, Mcltzer PS, Collins VP: Amplification of multiple genes from chromosomal region 12q 13-14 in human malignant gliomas: Preliminary’ mapping of the antplicons shows preferential involvement of CDK4, SAS, and MDM2., Cancer Res 1994;54:4299-4303.
21. Li Y., Jenkins CW., Nichols MA., Xiong Y: Cell cycle expression and p53 regulation of the cy-clin-dcpcndcnt kinase inhibitor p21., Oncogene 1994;9:2261-2268.
22. Gu Y., Turck CW., Morgan DO: Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit., Nature 1993:366:707-710.
23. Harper JW, Adami GR., Wei N, Keyomarsi K, Elledge SJ: The p21 Cdk-interacting protein Cipl is a potent inhibitor of G1 cyclin-depen-dent kinases., Cell 1993:75:805-816.
24. Van Meir EG., Polverini PJ., Chazin VR, Huang H-JS., de Tribolet N, Cavenee WK: Release of an inhibitor of angiogenesis upon induction of wild-type p53 expression in glioblastoma cells., Nat Genet 1994;8:171-176.
25. Folkman J., Cotran R: Relation of vascular proliferation to tumor growth., Exp Pathol 1976: 16:207-248.
26. Brem S., Cotran R, Folkman J: Tumor angiogenesis: A quantitative method for histologic grading., J Natl Cancer Inst 1972:48:347-356.
27. Takahashi JA., Fukumoto M., Igarashi K., Oda Y., Kikuchi H., Hatanaka M: Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas., J Neurosurg 1992:76:792-798.
28. Ueba T., Nosaka T., Takahashi JA., Shibata F., Florkiewicz RZ., Vogelstein B, Oda Y., Kikuchi H, Hatanaka M: Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and hepatocellular carcinoma cells., Proc Natl Acad Sci USA 1994:91: 9009-9013.
29. Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo., Nature 1992:359:845-848.
30. Kieser A, Weich HA, Brandncr G, Marme D, Kolch W: Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression., Oncogene 1994:9: 963-969.
31. Hermanson M., Funa K., Hartman M., Claesson Welsh L., Heldin CH, Westcrmark B., Nistcr M: Platelet-derived growth factor and its receptors in human glioma tissue: Expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops., Cancer Res 1992:52:3213-3219.
32. Nistcr M, Claesson WL, Eriksson A, Heldin CH, Wcstermark B: Differential expression of platelet-derived growth factor receptors in human glioma cell lines., J Biol Chem 1991:266: 16755-16763.
33. Fleming TP., Saxena A, Clark WC, Robertson JT, Oldfield EH., Aaronson SA., Ali IU: Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors., Cancer Res 1992:52:4550-4553.
34. Schcck AC., Mehta BM, Beikman MK, Shapiro JR: BCNU-resistant human glioma cells with over-representation of chromosomes 7 and 22 demonstrate increased copy number and expression of platelet-derived growth factor genes Genes Chromosom Cancer 1993:8:137-148.
35. James CD, Carlbom E., Dumanski JP., Hansen M, Nordenskjold M., Collins VP, Cavenee WK: Clonal genomic alterations in glioma malignancy stages., Cancer Res 1988,48:5546-5551.
36. Fults D., Pedone CA, Thomas GA., White R: Allelctype of human malignant astrocytoma., Cancer Res 1990:50:5784-5789.
37. Rubio MP, Correa KM., Ramesh V., MacCollin MM., Jacoby LB, von Deimling A, Gusella JF., Louis DN: Analysis of the neurofibromatosis 2 gene in human ependymomas and astrocytomas., Cancer Res 1994:54:45-47.
38. Ransom DT., Ritland SR., Kimmel DW, Mocr-tel CA, Dahl RJ., Scheithauer BW, Kelly PJ., Jenkins RB: Cytogenetic and loss of heterozygosity studies in ependymomas, pilocytic astrocytomas., and oligodendrogliomas., Genes Chromosom Cancer 1992;5:348-356.
39. James CD, He J, Carlbom E., Nordenskjold M., Cavenee WK, Collins VP: Chromosome 9 deletion mapping reveals interferon-alpha and in-tcrferon-bcta-1 gene deletions in human glial tumors., Cancer Res 1991:51:1684-1688.
40. Olopadc OI., Jenkins RB., Ransom DT, Malik K., Pomykala H, Nobori T, Cowan JM, Rowley JD., Diaz MO: Molecular analysis of deletions of the short arm of chromosome 9 in human gliomas., Cancer Res 1992:52:2523-2529.
41. Mizuno M, Yoshida J., Sugita K., Inoue I., Seo H., Hayashi Y., Koshizaka T, Yagi K: Growth inhibition of glioma cells transfected with the human beta-interferon gene by liposomes coupled with a monoclonal antibody., Cancer Res 1990;50:7826-7829.
42. James CD, He J., Collins VP, Allalunis-Tumcr MJ., Day RSI: Localization of chromosome 9p homozygous deletions in glioma cell lines with markers constituting a continuous linkage group., Cancer Res 1993:53:3674-3676.
43. Kamb A., Shaltuck-Eidens D., Ecles R., Liu Q, Gruis NA, Ding W, Hussey C, Tran T., Miki Y., Wcavcr-Fcldhaus J, McClure M, Ailkcn JF, Anderson DE., Bergman W., Frants R., Goldgar DE., Green A., MacLennan R, Martin NG, Meyer LJ, Youl P, Zone JJ., Skolnick M., Can-non-Albright LA: Analysis of the pl6 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus., Natl Genet 1994;8:22-26.
44. Kamb A., Gruis NA, Weaver FJ., Liu Q., Harsh-man K., Tavtigian SV, Stockert E, Day RR, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types., Science 1994;264:436-440.
45. Nobori T, Miura K., Wu DJ., Lois A., Takabaya-shi K, Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers., Nature 1994;368:753-756.
46. Mori T, Miura K, Aoki T, Nishihira T, Mori S, Nakamura Y: Frequent somatic mutation of the MTS1/CDKI (multiple tumor suppressor cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma., Cancer Res 1994;54:3396-3397.
47. Caldas C, Hahn SA, da Costa LT., Rcdston MS, Schulte M., Seymour AB., Weinstein CL, Hru-ban RH, Yeo CJ., Kern SE: Frequent somatic mutations and homozygous deletions of the pi6 (MTS1) gene in pancreatic adenocarcinoma., Nat Genet 1994:8:27-32.
48. Spruck CR., Gonzalez ZM, Shibata A, Simo-neau AR., Lin MF, Gonzales F, Tsai YC, Jones PA: pl6 gene in uncultured tumours., Nature 1994;370:183-184.
49. Serrano M., Hannon GJ, Beach DA: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4., Nature 1993;366:704-707.
50. Ohta M., Nagai H, Shimizu M., Rasio D, Berd D., Mastrangelo M, Singh AD., Shields JA., Shields CL, Croce CM., Huebner K: Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene., CDK4I, in melanoma., Cancer Res 1994;54:5269-5272.
51. Zhang SY., Klein SA, Sauter ER., Shatarcnko M, Mitsunaga S, Nobori T, Carson DA, Ridge JA, Goodrow TL: Higher frequency of alterations in the pl6/CDKN2genein squamous cell carcinoma cell lines than in primary tumors of the head and neck., Cancer Res 1994:54:5050-5053.
52. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PAT., Ally DS, Sheahan MD., Clark WH Jr., Tucker MA., Dracopoli NC: Germline p 16 mutations in familial melanoma., Nat Genet 1994;8:15-21.
53. Peter M., Herskowitz I: Joining the complex: Cyclin-dependent kinase inhibitory proteins and the cell cycle., Cell 1994;79:181-184.
54. Hunter T, Pines J: Cyclins and cancer, II: Cyclin Dand CDK inhibitors come of age., Cell 1994;79:573-582.
55. INK4in human cancer., Proc Natl Acad Sci USA 1994:91: 11045-11049.
56. 1NK4protein is restricted to the subset of lung cancer lines that retains wild-type RB., Oncogene 1994:9:3375-3378.
57. IU., Cancer Res 1994;54:5816-5820.
58. NK4or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines., Cancer Res 1995;55: 4833-4836.
59. Arap W, Nishikawa R., Fumari FB., Cavenee WK, Huang H-JS: Replacement of the p 16/ CDKN2 gene suppresses human glioma growth., Cancer Res 1995;55:1351-1354.
60. mk4) in human breast carcinomas., Cancer Res 1994;54:5262-5264.
61. Cairns P., Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, Tokino K, van der Riet P., Blaugrund JE, Sidransky D: Rates of p 16 (MTS1) mutations in primary tumors with 9p loss., Science 1994;265:415-417.
62. Giani C, Finocchiaro G: Mutation rate of the CDKN2 gene in malignant gliomas., Cancer Res 1994:54:6338-6339.
63. Ueki K, Rubio M-P., Ramesh V, Correa KM., Rutter JL., von Deimling A., Buckler AJ., Gusel-la JF, Louis DN: MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p., Hum Mol Genet 1994;3:1841-1845.
64. Jen J., Harper JW, Bigner SH, Bigner DD., Papadopoulos N, Markowitz S., Willson JKV, Kinzler KW., Vogclstein B: Deletion of pi 6 and pi 5 genes in brain tumors., Cancer Res 1994; 54:6353-6358.
65. Schmidt EE., Ichintura K., Reifenberger G, Collins VP: CDKN2 pl6MTSD gene deletion or CDK4 amplification occurs in the majority of glioblastomas., Cancer Res 1994;54:632t-6324.
66. NKJexpression is frequent in high-grade gliomas., Cancer Res 1995:55:1941-1945.
67. He J., Allen JR., Collins VP., Allalunis-Turner MJ, Godbout R., Day R Sr., James CD: CDK4 amplification is an alternative mechanism to pl6 gene homozygous deletion in glioma cell lines., Cancer Res 1994;54:5804-5807.
68. Venter DJ, Thomas DG: Multiple sequential molecular abnormalities in the evolution of human gliomas., BrJ Cancer 1991;63:753-757.
69. Henson JW., Schnitkcr BL., Correa KM., von Deimling A, Fassbender F, Xu HJ., Benedict WF., Yandc DW, Louis DN: The retinoblastoma gene is involved in malignant progression of astrocytomas., Ann Neurol 1994:36:714-721.
70. Von Deimling A, Nagel J, Bender B., J-enartz D., Schramm J, Louis DN., Wiestler OD: Deletion mapping of chromosome 19 in human gliomas., Int J Cancer 1994;57:676-680.
71. Von Deimling A, Louis DN, von Ammon K, Petersen I, Wiestler OD, Scizinger BR: Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas., Cancer Res 1992:52:4277-4279.
72. Seizinger BR, Klinger HP., Junien C., Nakamura Y., Lcbeau M, Cavenee W, Emanuel B, Ponder B, Naylor S, Mitclman F, Louis D., Mcnon A, Ncwsham I., Decker J., Kaclbling M., Henry I., Vondeimling A: Report of the Committee on Chromosome and Gene Loss in Human Neoplasia., Cytogenet Cell Genet 1991:58:1080-1096.
73. Rubio MP, Correa KM, Ueki K, Mohrenweiser HW, Gusella JF, von Deimling A, Louis DN: The putative glioma tumor suppressor gene on chromosome 19q maps between APOC2 and HRC., Cancer Res 1994;54:4760-4763.
74. Yong WH, Ueki K., Chou D, Reeves SA., von Deimling A, Gusella JF, Mohrenweiser HW, Buckler AJ, Louis DN: Cloning of a highly conserved human protein serine-threonine phosphatase gene from the glioma candidate region on chromosome 19q 13.3., Genomics 1995;29: 533-536.
75. Russell DS, Rubinstein LJ: Pathology of Tumors of the Central Nervous System., London., Arnold, 1989.
76. Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B: Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification., Proc Natl Acad Sci USA 1987;84:6899-6903.
77. Libermann TA., Nusbaum HR, Razon N, Kris R., Lax I., Sorcq H, Whittle N, Watcrfield MD, Ullrich A, Schlessinger J: Amplification-enhanced expression, and possible rearrangement of the EGF receptor gene in primary human brain tumors of glial origin., Nature 1985:313: 144-147.
78. Bigner SH., Humphrey PA., Wong AJ, Vogelstein B., Mark J., Friedman HS., Bigner DD: Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts., Cancer Res 1990:50:8017-8022.
79. Von Deimling A, Louis DN, von Ammon K., Petersen I., Hoell T, Chung RY., Martuza RL., Schoenfcld DA, Yasargil MG., Wiestlcr OD, el ai: Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme., J Neurosurg 1992;77:295-301.
80. Hurtt MR., Moossy J., Donovan-Peluso M., Locker J: Amplification of epidermal growth factor receptor gene in gliomas: Histopathologv and prognosis., J Neuropathol Exp Neurol 1992;51:84-90.
81. Ekstrand AJ., James CD., Cavenee WK, Seliger B, Pcttersson RF, Collins VP: Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo., Cancer Res 1991;51:2164-2172.
82. Fujimoto M., Weaker FJ, Herbert DC, Sharp ZD., Sheridan PJ, Story JL: Expression of three viral oncogenes (v-.st.v, v-myc, v-fos) in primary human brain tumors of neuroectodermal origin., Neurology 1988:38:289-293.
83. Orian JM., Vasilopoulos K, Yoshida S, Kaye AH., Chow C’W., Gonzales MF: Overexpression of multiple oncogenes related to histological grade of astrocytic glioma., Br J Cancer 1992; 66:106-112.
84. Fuller GN., Bigncr SI I: Amplified cellular oncogenes in neoplasms of the human central nervous system., Mutat Res 1992:276:299-306.
85. Collins VP: Amplified genes in human gliomas., Semin Cancer Biol 1993;4:27-32.
86. Takenaka N, Mikoshiba K., Takamatsu K., Tsu-kada Y, Ohtani M., Toya S: Immunohistochem-ical detection of the gene product of Rous sarcoma virus in human brain tumors., Brain Res 1985:337:201-207.
87. Schlegel J., Mcrdcs A., Stumm G, Albert FK, Forsting M., Hynes N, Kiessling M: Amplification of the epidermal growth factor receptor gene correlates with different growth behaviour in human glioblastoma., Int J Cancer 1994;56: 72-77.
88. Jaros E., Perry RH., Adam L., Kelly PJ., Crawford PJ., Kalbag RM, Mendelow AD., Sengupta RP, Pearson AD: Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours., Br J Cancer 1992;66:373-385.
89. Sugawa N., Ekstrand AJ, James CD, Collins VP: Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas., Proc Natl Acad Sci USA 1990:87:8602-8606.
90. Ekstrand AJ., Sugawa N, James CD., Collins VP: Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N-and/or C-terminal tails., Proc Nail Acad Sci USA 1992;89:4309-4313.
91. Humphrey PA., Wong AJ., Vogelstein B., Zalul-sky MR., Fuller GN., Archer GE, Friedman HS, Kwatra MM., Bigncr SH, Bigner DD: Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma., Proc Natl Sci USA 1990:87:4207-4211.
92. Malden LT, Novak U., Kaye AH., Burgess AW: Selective amplification of the cytoplasmic domain of the epidermal growth factor receptor gene in glioblastoma multiformc., Cancer Res 1988;48:2711-2714.
93. Wong AJ., Ruppcrt JM., Bigner SH., Grzeschik CH., Humphrey PA, Bigner DS., Vogelstein B: Structural alterations of the epidermal growth factor receptor gene in human gliomas., Proc Natl Acad Sci USA 1992;89:2965-2969.
94. Yamazaki H., Ohba Y., Tamaoki N., Shibuya M: A deletion mutation within the ligand binding domain is responsible for activation of epidermal growth factor receptor gene in human brain tumors., Jpn J Cancer Res 1990:81:773-779.
95. Nishikawa R., Xiang-Dong J., Harmon RC., Lazar CS., Gill GN., Cavenee WK, Huang H-JS: A mutant epidermal growth factor receptor common in human glioma confers enhanced tu-morigenicity., Proc Natl Acad Sci USA 1994; 91:7727-7731.
96. Goldman CK., Kim J, Wong WL, King V., Brock T., Gillespie GY: Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: A model of glioblastoma multiforme pathophvsiology., Mol Biol Cell 1993:4:121-133.
97. Bigncr SH., Mark J., Burger PC., Mahaley MJ., Bullard DE., Muhlbaier LII., Bigncr DD: Specific chromosomal abnormalities in malignant human gliomas., Cancer Res 1988:48:405-411.
98. Fujimoto M., Fulls DW., Thomas GA, Nakamura Y, Hciibrun MP., White R., Story JL., Naylor SL, Kagan HK, Sheridan PJ: Loss of heterozygosity on chromosome 10 in human glioblastoma multiforme., Genomics 1989;4:210-214.
99. Rasheed BK., Fuller GN, Friedman AH., Bigner DD., Bigner SH: Loss of heterozygosity for lOq loci in human gliomas., Genes Chromo-som Cancer 1992:5:75-82.
100. Karlbom AE., James CD, Boethius J, Cavenee WK., Collins VP, Nordenskjold M, Larsson C: Loss of heterozygosity in malignant gliomas involves at least three distinct regions on chromosome 10., Hum Genet 1993,92:169-174.
101. Fults D, Pedone C: Deletion mapping of the long arm of chromosome 10 in glioblastoma multiforme., Genes Chromosom Cancer 1993;7:173-177.
102. Pershousc MA, Stubblefield E, Hadi A., Killary AM, Y ung WK, Steck PA: Analysis of the functional role of chromosome 10 loss in human glioblastomas., Cancer Res 1993:53: 5043-5050.
103. Von Deimling A, von Ammon K., Schoenfeld D, Wiestler OD., Scizinger BR., Louis DN: Subsets of glioblastoma multiforme defined by molecular genetic analysis., Brain Pathol 1993:3:19-26.
104. Bello MJ., Vaquero J, de Campos JM., Kusak ME., Sarasa JL, Saez-Castresana J., Pestana A, Rey JA: Molecular analysis of chromosome 1 abnormalities in human gliomas reveals frequent loss of lp in oligodendroglia! tumors., Int J Cancer 1994:57:172-175.
105. Kraus JA, Koopmann J, Kaskel P., Maintz D, Brandner S, Schramm J, Louis DN., Wiestler OD, von Deimling A: Shared allelic losses on chromosomes lp and 19q suggest a common origin of oligodendroglioma and oligoastrocy-toma., J Neuropathol Exp Neurol 1995:54: 91-95.
106. Reifenberger J, Reifenbcrger G, Liu L, James CD, Wechsler W, Collins VP: Molecular genetic analysis of oligodendroglia! tumors shows preferential allelic deletions on 19q and 1 p., Am J Pathol 1994; 145:1175-1190.
107. Kim TS., Halliday AL., Hedley-Whyte ET, Convery K: Correlates of survival and the Daumas-Duport grading system for astrocytomas., J Neurosurg 1991;74:27-37.
108. Burger PC, Vogel FS, Green SB., Strike TA: Glioblastoma multiforme and anaplastic astrocytoma., Pathologic criteria and prognostic implications., Cancer 1985:56:1106-1111.
109. Burger PC., Green SB: Patient age, histologic features, and length of survival in patients with glioblastoma multiforme., Cancer 1987; 59:1617-1625.